Cyclo Therapeutics, Inc.

Cyclo Therapeutics, Inc., through various name changes originally started in 1990 and a R&D specialty company. Currently the company is pursuing treatment of a rare disease, Niemann Pick Type C. More broadly, we are a clinical stage biotechnology company focused on the use of cyclodextrins in drug development. The Company has launched clinical trial programs, initially in Europe and the US, for its Trappsol® Cyclo™ as treatment for Neiman-Pick Type C disease (NPC). We also sell cyclodextrins and related products to the pharmaceutical, nutritional and other industries.